Comprehensive Stock Comparison
Compare BlackRock Technology and Private Equity Term Trust (BTX) vs XOMA Royalty Corp. (XOMA) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth |  XOMA | 498.7% revenue growth vs BTX's -81.1% |
| Value |  BTX | Lower P/E (38.9x vs 39.7x) |
| Quality / Margins | BTX | 87.7% net margin vs XOMA's 41.1% |
| Stability / Safety | XOMA | Beta 0.82 vs BTX's 1.16 |
| Dividends | BTX | 12.9% yield, 1-year raise streak, vs XOMA's 1.8% |
| Momentum (1Y) | XOMA | +22.5% vs BTX's +6.8% |
| Efficiency (ROA) | XOMA | 7.3% ROA vs BTX's 1.8%, ROIC -37.6% vs 1.4% |
Who Each Stock Is For
Income & stability
BTXDividend streak 1 yrs, beta 1.16, yield 12.9%
Growth exposure
XOMARev growth 498.7%, EPS growth 59.2%, 3Y rev CAGR -9.3%
Long-term compounding (10Y)
XOMA46.9% 10Y total return vs BTX's -45.5%
Sleep-well-at-night portfolio
XOMALower volatility, beta 0.82, current ratio 5.15x
Defensive / Recession hedge
XOMABeta 0.82, yield 1.8%, current ratio 5.15x
Business Model
What each company does and how it makes money
BlackRock Technology and Private Equity Term Trust is a closed-end investment fund that pools investor capital to invest primarily in mid- and small-capitalization growth companies in the technology and healthcare sectors. It generates returns through capital appreciation and dividend income from its equity portfolio, with performance tied to the success of its underlying investments. The fund's key advantage is BlackRock's extensive research capabilities and access to innovative companies that traditional investors might overlook.
XOMA Royalty Corp is a biotechnology royalty aggregator that acquires future economic rights to pre-commercial therapeutic candidates licensed to pharmaceutical partners. It generates revenue primarily through milestone payments and royalties from its portfolio of approximately 70 early to mid-stage clinical assets—typically earning a percentage of future drug sales if the therapies succeed. The company's moat lies in its specialized expertise in evaluating clinical-stage assets and structuring royalty agreements that provide diversified exposure to potential blockbuster drugs without bearing development costs.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
BTX 3XOMA 2BTX4/4 metricsXOMA2/3 metricsBTX5/8 metricsXOMA5/6 metricsBTX2/2 metricsBTX leads in 3 of 6 categories (Financial Metrics, Profitability & Efficiency). XOMA leads in 2 (Valuation Metrics, Total Returns). 1 tied.
Financial Metrics (TTM)
XOMA and BTX operate at a comparable scale, with $47M and $41M in trailing revenue. BTX is the more profitable business, keeping 87.7% of every revenue dollar as net income compared to XOMA's 41.1%.
| Metric | BTXBlackRock Technol… | XOMAXOMA Royalty Corp. |
|---|---|---|
| RevenueTrailing 12 months | $41M | $47M |
| EBITDAEarnings before interest/tax | — | $22M |
| Net IncomeAfter-tax profit | — | $19M |
| Free Cash FlowCash after capex | — | $5M |
| Gross MarginGross profit ÷ Revenue | +100.0% | +93.8% |
| Operating MarginEBIT ÷ Revenue | +87.7% | +4.1% |
| Net MarginNet income ÷ Revenue | +87.7% | +41.1% |
| FCF MarginFCF ÷ Revenue | +6.8% | +11.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +29.9% |
| EPS Growth (YoY)Latest quarter vs prior year | — | +144.0% |
Valuation Metrics
| Metric | BTXBlackRock Technol… | XOMAXOMA Royalty Corp. |
|---|---|---|
| Market CapShares × price | $773M | $316M |
| Enterprise ValueMkt cap + debt − cash | $773M | $334M |
| Trailing P/EPrice ÷ TTM EPS | 38.94x | -16.03x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 39.71x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 21.64x | — |
| Price / SalesMarket cap ÷ Revenue | 18.99x | 11.10x |
| Price / BookPrice ÷ Book value/share | 0.80x | 3.78x |
| Price / FCFMarket cap ÷ FCF | 2.79x | — |
Profitability & Efficiency
XOMA delivers a 17.9% return on equity — every $100 of shareholder capital generates $18 in annual profit, vs $2 for BTX. On the Piotroski fundamental quality scale (0–9), XOMA scores 4/9 vs BTX's 3/9, reflecting mixed financial health.
| Metric | BTXBlackRock Technol… | XOMAXOMA Royalty Corp. |
|---|---|---|
| ROE (TTM)Return on equity | +1.9% | +17.9% |
| ROA (TTM)Return on assets | +1.8% | +7.3% |
| ROICReturn on invested capital | +1.4% | -37.6% |
| ROCEReturn on capital employed | +1.8% | -19.4% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | — | 1.46x |
| Net DebtTotal debt minus cash | $0 | $18M |
| Cash & Equiv.Liquid assets | — | $102M |
| Total DebtShort + long-term debt | $0 | $119M |
| Interest CoverageEBIT ÷ Interest expense | 2313.25x | 0.67x |
Total Returns (with DRIP)
A $10,000 investment in XOMA five years ago would be worth $7,158 today (with dividends reinvested), compared to $5,453 for BTX. Over the past 12 months, XOMA leads with a +22.5% total return vs BTX's +6.8%. The 3-year compound annual growth rate (CAGR) favors XOMA at 7.4% vs BTX's 5.8% — a key indicator of consistent wealth creation.
| Metric | BTXBlackRock Technol… | XOMAXOMA Royalty Corp. |
|---|---|---|
| YTD ReturnYear-to-date | +0.5% | -5.5% |
| 1-Year ReturnPast 12 months | +6.8% | +22.5% |
| 3-Year ReturnCumulative with dividends | +18.3% | +23.9% |
| 5-Year ReturnCumulative with dividends | -45.5% | -28.4% |
| 10-Year ReturnCumulative with dividends | -45.5% | +46.9% |
| CAGR (3Y)Annualised 3-year return | +5.8% | +7.4% |
Risk & Volatility
XOMA is the less volatile stock with a 0.82 beta — it tends to amplify market swings less than BTX's 1.16 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BTX currently trades 88.3% from its 52-week high vs XOMA's 66.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BTXBlackRock Technol… | XOMAXOMA Royalty Corp. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.16x | 0.82x |
| 52-Week HighHighest price in past year | $7.50 | $39.92 |
| 52-Week LowLowest price in past year | $5.10 | $18.35 |
| % of 52W HighCurrent price vs 52-week peak | +88.3% | +66.3% |
| RSI (14)Momentum oscillator 0–100 | 47.3 | 49.0 |
| Avg Volume (50D)Average daily shares traded | 908K | 482K |
Analyst Outlook
For income investors, BTX offers the higher dividend yield at 12.93% vs XOMA's 1.77%.
| Metric | BTXBlackRock Technol… | XOMAXOMA Royalty Corp. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $68.25 |
| # AnalystsCovering analysts | — | 10 |
| Dividend YieldAnnual dividend ÷ price | +12.9% | +1.8% |
| Dividend StreakConsecutive years of raises | 1 | 0 |
| Dividend / ShareAnnual DPS | $0.86 | $0.47 |
| Buyback YieldShare repurchases ÷ mkt cap | +12.0% | +0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 21 | Mar 26 | Change |
|---|---|---|---|
| BlackRock Technolog… (BTX) | 100 | 33.57 | -66.4% |
| XOMA Royalty Corp. (XOMA) | 100 | 64.49 | -35.5% |
XOMA Royalty Corp. (XOMA) returned -28% over 5 years vs BlackRock Technolog… (BTX)'s -45%.
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| BlackRock Technolog… (BTX) | $-640M | $41M | +106.4% |
| XOMA Royalty Corp. (XOMA) | $55M | $28M | -48.6% |
XOMA Royalty Corp.'s revenue grew from $55M (2015) to $28M (2024) — a -7.1% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| BlackRock Technolog… (BTX) | 100.1% | 87.7% | -12.4% |
| XOMA Royalty Corp. (XOMA) | -37.2% | -48.5% | -30.6% |
XOMA Royalty Corp.'s net margin went from -37% (2015) to -49% (2024).
Chart 4P/E Ratio History — 3 Years
| Stock | 2017 | 2021 | Change |
|---|---|---|---|
| XOMA Royalty Corp. (XOMA) | 48.8 | 32.1 | -34.2% |
XOMA Royalty Corp. has traded in a 32x–57x P/E range over 3 years; current trailing P/E is ~-16x.
Chart 5EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| BlackRock Technolog… (BTX) | -2.58 | 0.17 | +106.6% |
| XOMA Royalty Corp. (XOMA) | -3.5 | -1.65 | +52.9% |
XOMA Royalty Corp.'s EPS grew from $-3.50 (2015) to $-1.65 (2024).
Chart 6Free Cash Flow — 5 Years
BlackRock Technology and Private Equity Term Trust generated $277M FCF in 2024 (+106% vs 2021). XOMA Royalty Corp. generated $-14M FCF in 2024 (-260% vs 2021).
BTX vs XOMA: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is BTX or XOMA a better buy right now?
BlackRock Technology and Private Equity Term Trust (BTX) offers the better valuation at 38.9x trailing P/E, making it the more compelling value choice. Analysts rate XOMA Royalty Corp. (XOMA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — BTX or XOMA?
Over the past 5 years, XOMA Royalty Corp. (XOMA) delivered a total return of -28.4%, compared to -45.5% for BlackRock Technology and Private Equity Term Trust (BTX). A $10,000 investment in XOMA five years ago would be worth approximately $7K today (assuming dividends reinvested). Over 10 years, the gap is even starker: XOMA returned +46.9% versus BTX's -45.5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — BTX or XOMA?
By beta (market sensitivity over 5 years), XOMA Royalty Corp. (XOMA) is the lower-risk stock at 0.82β versus BlackRock Technology and Private Equity Term Trust's 1.16β — meaning BTX is approximately 42% more volatile than XOMA relative to the S&P 500.
04Which has better profit margins — BTX or XOMA?
BlackRock Technology and Private Equity Term Trust (BTX) is the more profitable company, earning 87.7% net margin versus -48.5% for XOMA Royalty Corp. — meaning it keeps 87.7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BTX leads at 87.7% versus -140.3% for XOMA. At the gross margin level — before operating expenses — BTX leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — BTX or XOMA?
All stocks in this comparison pay dividends. BlackRock Technology and Private Equity Term Trust (BTX) offers the highest yield at 12.9%, versus 1.8% for XOMA Royalty Corp. (XOMA).
06Is BTX or XOMA better for a retirement portfolio?
For long-horizon retirement investors, XOMA Royalty Corp. (XOMA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.82), 1.8% yield). Both have compounded well over 10 years (XOMA: +46.9%, BTX: -45.5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between BTX and XOMA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: BTX is a small-cap income-oriented stock; XOMA is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.